Masaki Mogi Selected Research

Masaki Mogi Research Topics

Disease

25	Cognitive Dysfunction 04/2020 - 07/2006
21	Hypertension (High Blood Pressure) 01/2022 - 04/2004
19	Stroke (Strokes) 01/2022 - 11/2006
14	Vascular Remodeling 01/2020 - 02/2006
12	Inflammation (Inflammations) 04/2018 - 04/2006
11	Insulin Resistance 05/2022 - 09/2005
11	Vascular System Injuries 01/2020 - 09/2005
10	Atherosclerosis 01/2020 - 04/2005
9	Brain Ischemia (Cerebral Ischemia) 11/2015 - 09/2006
8	Dementia (Dementias) 04/2020 - 09/2009
8	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 10/2008
7	Body Weight (Weight, Body) 05/2022 - 07/2009
5	Neointima 01/2020 - 11/2012
5	Cardiomegaly (Heart Hypertrophy) 01/2016 - 10/2006
5	Type 2 Diabetes Mellitus (MODY) 12/2015 - 02/2008
5	Diabetes Mellitus 05/2013 - 04/2004
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2012 - 04/2004
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2011 - 07/2006
3	Muscle Weakness 01/2021 - 01/2019
3	Anaphylaxis (Anaphylactic Shock) 01/2021 - 07/2020
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2002
3	Brain Injuries (Brain Injury) 10/2018 - 09/2008
3	Obesity 01/2016 - 04/2004
3	Glucose Intolerance 08/2009 - 12/2006
2	Vascular Diseases (Vascular Disease) 02/2021 - 01/2020
2	Chronic Renal Insufficiency 01/2021 - 09/2016
2	Neurologic Manifestations (Neurological Manifestations) 10/2018 - 11/2006
2	Fetal Growth Retardation (Intrauterine Growth Retardation) 03/2018 - 01/2016
2	Ischemia 11/2015 - 09/2008
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2013 - 04/2009
2	Multiple Sclerosis 01/2013 - 04/2009
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2010 - 09/2009

Drug/Important Bio-Agent (IBA)

25	Angiotensin IIIBA 01/2021 - 04/2005
19	Type 2 Angiotensin ReceptorIBA 01/2019 - 09/2005
12	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 12/2004
11	olmesartanIBA 11/2011 - 04/2005
10	compound 21IBA 10/2018 - 01/2012
9	Proteins (Proteins, Gene)FDA Link 04/2018 - 12/2004
8	Insulin (Novolin)FDA Link 01/2022 - 02/2006
8	AngiotensinsIBA 01/2018 - 10/2006
8	Polyethylene (Polythene)IBA 01/2016 - 09/2005
8	Type 1 Angiotensin ReceptorIBA 03/2014 - 10/2006
7	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 02/2009
7	Superoxides (Superoxide)IBA 04/2020 - 10/2006
7	ApolipoproteinsIBA 02/2008 - 04/2005
6	Angiotensin Receptor AntagonistsIBA 10/2020 - 12/2006
6	Telmisartan (Micardis)FDA Link 05/2012 - 01/2008
5	Biomarkers (Surrogate Marker)IBA 12/2019 - 12/2004
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 01/2012
5	PPAR gammaIBA 10/2018 - 10/2008
5	Messenger RNA (mRNA)IBA 01/2016 - 07/2006
5	Angiotensin II Type 1 Receptor BlockersIBA 05/2012 - 12/2006
5	Valsartan (Vals)FDA Link 05/2011 - 09/2005
5	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 02/2009 - 10/2006
4	SaltsIBA 01/2022 - 12/2007
4	AngiotensinogenIBA 01/2021 - 02/2009
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2020 - 01/2013
4	Amyloid (Amyloid Fibrils)IBA 04/2020 - 02/2012
4	Angiotensin-Converting Enzyme 2IBA 01/2020 - 11/2011
4	2-chloro-5-nitrobenzanilideIBA 10/2018 - 10/2008
4	CytokinesIBA 04/2018 - 01/2015
4	ReninIBA 05/2011 - 02/2009
3	CholesterolIBA 05/2022 - 12/2007
3	MicroRNAs (MicroRNA)IBA 02/2021 - 01/2019
3	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 04/2004
3	Rocuronium (Zemuron)FDA LinkGeneric 01/2021 - 07/2020
3	angiotensin I (1-7)IBA 01/2020 - 03/2014
3	EnzymesIBA 01/2018 - 10/2014
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2016 - 11/2012
3	Nifedipine (Adalat)FDA LinkGeneric 08/2010 - 11/2007
3	CalciumIBA 02/2009 - 07/2002
3	azelnidipineIBA 12/2006 - 07/2005
2	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 09/2013
2	Pharmaceutical PreparationsIBA 01/2022 - 09/2016
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 01/2017
2	Monocyte Chemoattractant ProteinsIBA 04/2020 - 11/2007
2	NADP (NADPH)IBA 04/2020 - 10/2018
2	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2020 - 10/2006
2	RNA (Ribonucleic Acid)IBA 01/2020 - 02/2002
2	Interferon Regulatory Factor-1 (Interferon Regulatory Factor 1)IBA 10/2018 - 10/2016
2	salicylhydroxamic acid (SHAM)IBA 01/2018 - 11/2015
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2016 - 11/2012
2	LipidsIBA 01/2016 - 06/2006
2	azilsartanIBA 04/2015 - 07/2014
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2015 - 11/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 09/2005
2	Biological ProductsIBA 09/2013 - 03/2005
2	AldosteroneIBA 09/2013 - 04/2006
2	propagermanium (Ge 132)IBA 11/2012 - 06/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 11/2007
2	Losartan (Cozaar)FDA LinkGeneric 08/2010 - 10/2008
2	p38 Mitogen-Activated Protein KinasesIBA 05/2010 - 10/2008
2	Amyloid beta-PeptidesIBA 10/2009 - 09/2009
2	candesartanIBA 12/2007 - 09/2006
2	Eplerenone (Inspra)FDA LinkGeneric 07/2007 - 04/2006
2	Amlodipine (Norvasc)FDA LinkGeneric 11/2006 - 06/2006
2	Apolipoproteins E (ApoE)IBA 11/2006 - 09/2005
2	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 11/2006 - 06/2006

Therapy/Procedure

2	Therapeutics 01/2022 - 07/2005
2	Oral Administration 01/2017 - 12/2007